BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease

Go back to BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
(NASDAQ: BIVI) Delayed: 1.37 -0.06 (4.2%)
Previous Close $1.43    52 Week High $0.40 
Open $1.41    52 Week Low $0.17 
Day High $1.43    P/E N/A 
Day Low $1.31    EPS $0.00 
Volume 120,889